According to Horizon Therapeutics
's latest financial reports the company has $2.46 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $2.35 B | 48.88% |
2021-12-31 | $1.58 B | -24.02% |
2020-12-31 | $2.07 B | 93.25% |
2019-12-31 | $1.07 B | 12.26% |
2018-12-31 | $0.95 B | 27.6% |
2017-12-31 | $0.75 B | 47.6% |
2016-12-31 | $0.50 B | -40.78% |
2015-12-31 | $0.85 B | 292.86% |
2014-12-31 | $0.21 B | 171.88% |
2013-12-31 | $80.48 M | -22.68% |
2012-12-31 | $0.10 B | 479.36% |
2011-12-31 | $17.96 M | 233.69% |
2010-12-31 | $5.38 M | -24.8% |
2009-12-31 | $7.16 M | -49.1% |
2008-12-31 | $14.06 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $12.69 B | 414.89% | ๐บ๐ธ USA |
Amgen AMGN | $10.94 B | 344.04% | ๐บ๐ธ USA |
Merck MRK | $7.09 B | 187.79% | ๐บ๐ธ USA |
AstraZeneca AZN | $5.86 B | 137.76% | ๐ฌ๐ง UK |
Dr. Reddy's RDY | $0.86 B | -64.73% | ๐ฎ๐ณ India |